Data from DELIVER and ACHIEVE Clinicals Trial to be Presented - - Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on the Use of Splicing Correction as a Prognostic Biomarker ...

Exxon spent the past year moving a lab's operations from California to Baytown and plans to increase its number of employees ...

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Biden’s decision underscored two key challenges with the current CFIUS process: the absence of a clear tiered framework to ...

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

We recently published a list of 10 Best Stocks To Buy For Financial Stability. In this article, we are going to take a look ...

FC Dallas and the Houston Dynamo held an extended scrimmage today that consisted of two shortened games. The “starters” ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

As the temperatures continue to grow colder, a local company is hoping to bring warmth and comfort to some East Providence ...

The proposal, purported to save $83 billion over a decade, is a "dagger in the heart of all patient advocacy nonprofits," said the head of a cancer patient support group.

Entrada Therapeutics has secured authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to ...